Article
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Nature genetics - 1 Jul 2012
Zhang Zhenfeng, Lee Jae Cheol, Lin Luping, Olivas Victor, Au Valerie, LaFramboise Thomas, Abdel-Rahman Mohamed, Wang Xiaoqi, Levine Alan D, Rho Jin Kyung, Choi Yun Jung, Choi Chang-Min, Kim Sang-We, Jang Se Jin, Park Young Soo, Kim Woo Sung, Lee Dae Ho, Lee Jung-Shin, Miller Vincent A, Arcila Maria, Ladanyi Marc, Moonsamy Philicia, Sawyers Charles, Boggon Titus J, Ma Patrick C, Costa Carlota, Taron Miquel, Rosell Rafael, Halmos Balazs, Bivona Trever G
Abstract excerpt
Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance. Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors. Here, we report increased activation of AXL and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.